BRANFORD, Conn. / Jul 26, 2023 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in the Canaccord Genuity 43rd Annual Growth Conference taking place at the InterContinental Boston Hotel on August 7-10, 2023.
Jeff Hawkins, Quantum-Si's Chief Executive Officer, will participate in the panel discussion “The Next Generation of Proteomics from the Research and Clinical Perspectives” on Thursday, August 10, at 10:00 AM ET.
Additionally, Jeff Hawkins will participate in a fireside chat on Thursday, August 10, at 12:30 PM ET.
A live and archived webcast of the event will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing CompanyTM, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.
| Last Trade: | US$1.27 |
| Daily Change: | -0.07 -4.89 |
| Daily Volume: | 2,994,785 |
| Market Cap: | US$175.080M |
February 18, 2025 February 13, 2025 January 28, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
